| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/01/2002 | WO2002058637A2 Compositions and methods for diagnosis of neuropsychiatric disorders |
| 08/01/2002 | WO2002058636A2 Novel cannabimimetic ligands |
| 08/01/2002 | WO2002058635A2 Nicotine immunogens and antibodies and uses thereof |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058620A2 Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant |
| 08/01/2002 | WO2002045749A3 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 08/01/2002 | WO2002043712A3 Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002026733A3 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 08/01/2002 | WO2002022572A3 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002020031A3 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses |
| 08/01/2002 | WO2002016620A3 Modulation of stem cell differentiation |
| 08/01/2002 | WO2002014319A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 08/01/2002 | WO2002012190A3 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002004509A3 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 08/01/2002 | WO2002004019A3 Use of strains of the parapox ovis virus against organ fibrosis |
| 08/01/2002 | WO2002002505A3 Compounds to treat alzheimer's disease |
| 08/01/2002 | WO2002000684A3 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 08/01/2002 | WO2001098367A3 Neuroactive peptides for treatment of hypoxia and related conditions |
| 08/01/2002 | WO2001098279A3 Bis-arylsulfones |
| 08/01/2002 | WO2001090315A3 Production of neurons from stem cells |
| 08/01/2002 | WO2001089538A3 Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| 08/01/2002 | WO2001089537A3 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| 08/01/2002 | WO2001089536A3 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| 08/01/2002 | WO2001089319A3 Tryptophan source from plants and uses therefor |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001082914A3 Topical anesthetic/opioid formulations and uses thereof |
| 08/01/2002 | WO2001078654A3 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 08/01/2002 | WO2001078530A3 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001062290A3 Methods and compositions for improving sleep |
| 08/01/2002 | WO2000077040A9 Human intracellular signaling molecules |
| 08/01/2002 | US20020104113 Nav2 channel gene-deficient non-human animals |
| 08/01/2002 | US20020104108 Expression vector coding polypeptides for use in the treatment of alzheimer's dieases and tumors |
| 08/01/2002 | US20020103389 Klainetins and their derivatives, method for their preparation and use thereof |
| 08/01/2002 | US20020103372 Drying crystals of a mirtazapine hydrate to give anhydrous mirtazapine crystals having moisture <= 0.6% by weight when crystals are stored in the air having relative humidity 75% at 25 degree C. under atmospheric pressure for 500 hours |
| 08/01/2002 | US20020103371 Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives |
| 08/01/2002 | US20020103259 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 08/01/2002 | US20020103249 Combination of a serotonin reuptake inhibitor and irindalone |
| 08/01/2002 | US20020103245 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 08/01/2002 | US20020103242 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103237 For decreasing amphetamine-induced hyperactivity |
| 08/01/2002 | US20020103235 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103221 Such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide or prodrug thereof; for improving functional health of elderly/isolated |
| 08/01/2002 | US20020103211 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders |
| 08/01/2002 | US20020103209 Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine |
| 08/01/2002 | US20020103208 Useful in treatment of anxiety disorders, affective disorders such as depression, psychosis and schizophrenia, Parkinson's disease |
| 08/01/2002 | US20020103205 Muscarinic antagonists |
| 08/01/2002 | US20020103198 Acylamino cyclopropane derivatives |
| 08/01/2002 | US20020103190 Azo amino acids derivatives |
| 08/01/2002 | US20020103184 Cyclic malonamides as inhibitors of a beta protein production |
| 08/01/2002 | US20020103182 Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts" or AGEs |
| 08/01/2002 | US20020103178 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 08/01/2002 | US20020103172 Vitamin d3 derivatives |
| 08/01/2002 | US20020103166 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders |
| 08/01/2002 | US20020103162 Use of threo-methylphenidate compounds to enhance memory |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020103112 Wound healing and treatment of fibrosis |
| 08/01/2002 | US20020102711 Polypeptide for use in the treatment of cancer and immunological |
| 08/01/2002 | US20020102710 Polypeptide for use in the treatment of cancer, autoimmune diseases and inflammation |
| 08/01/2002 | US20020102707 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 08/01/2002 | US20020102684 Human phospholipase inhibitor |
| 08/01/2002 | US20020102643 Dorsal tissue affecting factor and compositions |
| 08/01/2002 | US20020102566 Identification of neural defects associated with the nucleosomal assembly protein 112 gene |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102302 Stabilized sustained release tramadol formulations |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020102261 Immunological control of beta-amyloid levels in vivo |
| 08/01/2002 | US20020102259 Methods and compositions for stimulating CD 45 and thereby suppressing microglial activation associated with Alzheimer's disease |
| 08/01/2002 | US20020100854 Furnace mount and method of installation |
| 08/01/2002 | US20020100185 Drying method for selectively removing volatile components from wet coatings |
| 08/01/2002 | DE10102977A1 Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose Test system for the development of therapeutics, in particular of drugs used to treat osteoporosis |
| 08/01/2002 | DE10101430A1 Lösliche cyclische Analoga Soluble cyclic analogues |
| 08/01/2002 | DE10101307A1 Fumarsäurederivate als NF-kappaB-Inhibitor Fumaric acid derivatives as NF-kappaB inhibitor |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2435883A1 Benzylamine analogue |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435781A1 Method for detecting of prions in a sample |
| 08/01/2002 | CA2435776A1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | CA2435647A1 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | CA2435566A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | CA2435418A1 Use of neurotoxic substances in producing a medicament for treating joint pains |
| 08/01/2002 | CA2435409A1 Novel cannabimimetic ligands |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434558A1 Imidazolyl derivatives as corticotropin releasing factor inhibitors |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2434226A1 Process for preparing non-hygroscopic sodium valproate composition |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2432122A1 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 08/01/2002 | CA2431970A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists |
| 08/01/2002 | CA2431904A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 08/01/2002 | CA2333494A1 Blood brain barrier modulation |